MBF-RIC

Phase 2Small molecule

SShanghai Jiao Tong University School of Medicine

MBF-RIC is one of 13 small molecule programs targeting Myeloid Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid MalignanciesRecruiting

Myeloid MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Myeloid Malignancies

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

5 2

Busulfex

Akero Therapeutics

Phase 3

1 3

Orencia

Bristol-Myers Squibb

Phase 2

1 4

Jakafi

Incyte

Phase 2

1 5

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 6

Trisenox

CCephalon

Phase 2

1 7

Rezlidhia

RRigel Pharmaceuticals

Phase 2

1 8

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 1

4 9

Fludara

Sanofi

Preclinical

2 10

Azacitidine or Decitabine

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Myeloid Malignancies

NCT05436561

Clinical

Trials by Indication[1]

Myeloid Malignancies1 trial

Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05436561·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MBF-RIC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MBF-RIC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MBF-RIC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Jiao Tong University School of Medicine

MBF-RIC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Myeloid Malignancies1 trial

References

Drug Info

Quick Facts

Related News